Bio Preventive Medicine Corp. (TPEX: 6810)
Health Care · Biotechnology · TW
NT$22.05
-4.13% today · -16.3% 1Y
Bio Preventive Medicine Corp. (TPEX: 6810) operates in the Biotechnology industry within the Health Care sector. The company is valued at $34.24M and employs 26 people.
Over the last twelve months the share price has lost 16.3%, trading between 16.50 and 46.00.
6810 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $34.24M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 0.53
- 52-week high
- NT$46.00
- 52-week low
- NT$16.50
- Avg volume (3M)
- —
- Shares outstanding
- 49.45M
- Employees
- 26
- Next earnings
- —
About Bio Preventive Medicine Corp.
Bio Preventive Medicine Corp., a biotechnology firm currently in the clinical development phase, specializes in the proactive identification and mitigation of various illnesses. The company develops comprehensive strategies for the prevention, screening, and ongoing oversight of chronic conditions and cancer treatment. A key offering is the DNlite test, a suite of proprietary and medically validated non-intrusive urine analyses designed to aid in the management of diabetic kidney disease, encompassing specific products like DNlite-IVD103 and DNlite-DN_Score. Established in 2014, its main operations are located in Zhubei, Taiwan.
- ISIN
- TW0006810005
- Founded
- 2014
- Listed since
- Aug 30, 2021
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.